[Open multicenter study of the differential diagnosis of erectile dysfunction with a papaverine-phentolamine combination (BY023)].
We report the results of an open multicenter clinical trial with 115 patients. The results of a pharmacological test using intracavernously applied mixture of papaverine and phentolamine were compared with the results of a multidisciplinary evaluation of erectile dysfunction. Sensitivity and specificity of our test were determined. The injection of our drug solution caused an increase in tumescence and/or rigidity in all patients. The evaluation of the dose dependent erectile response makes it possible to distinguish between the three main pathogenetic principles: non-vascular, arterial and venous etiology of erectile dysfunction. The pharmacological test requires one to four intracavernous injections of 0.5-3.0 ml of the drug solution (7.5-45 mg papaverine hydrochloride, 0.25-1.5 mg phentolamine mesylate).
Jünemann
K P
KP
Abteilung Urologie, Städtische Kliniken Kassel.
Jecht
E
E
Müller-Mattheis
V
V
Weiske
W H
WH
Wetterauer
U
U
Baccouche
M
M
Lühmann
R
R
Zentgraf
M
M
Bähren
W
W
Altwein
J E
JE
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D004338:Drug Combinations; D007172:Erectile Dysfunction / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine; D010410:Penile Erection / Q000187:drug effects; D010413:Penis / Q000098:blood supply; D010646:Phentolamine; D012039:Regional Blood Flow / Q000187:drug effects; D014463:Ultrasonography
D004338:Drug Combinations; C055514:papaverine, phentolamine drug combination; D010208:Papaverine; D010646:Phentolamine
Offene Multizenterstudie zur Differentialdiagnostik der erektilen Dysfunktion mit einer Papaverin-Phentolamin-Kombination (BY023).